Does the oncology community have a rejection bias when it comes to repurposed drugs? - Wikidata - wikimedia - TriplyDB

Does the oncology community have a rejection bias when it comes to repurposed drugs?

Does the oncology community have a rejection bias when it comes to repurposed drugs?

http://www.wikidata.org/entity/Q49884530

about

Does the oncology community have a rejection bias when it comes to repurposed drugs?

http://www.wikidata.org/entity/Q49884530

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Does the oncology community have a rejection bias when it comes to repurposed drugs?

@en

Does the oncology community have a rejection bias when it comes to repurposed drugs?

@nl

type

label

Does the oncology community have a rejection bias when it comes to repurposed drugs?

@en

Does the oncology community have a rejection bias when it comes to repurposed drugs?

@nl

prefLabel

Does the oncology community have a rejection bias when it comes to repurposed drugs?

@en

Does the oncology community have a rejection bias when it comes to repurposed drugs?

@nl

P1433

Q49884530-3ED29307-EDB6-406E-A85E-EF05E9867683

P1476

Q49884530-453FDBE6-C396-4722-B7A2-7D62098B2F13

P2093

Q49884530-4DB84DBA-BCF0-4A38-AB41-689541CB6EE2

Q49884530-6B2B4361-8052-4B89-9695-B223F7AE786F

Q49884530-7AFD50C7-B344-4145-BB31-43316965DD0F

Q49884530-D9396627-BAD9-4F94-AE97-796A6FF0B768

P2860

Q49884530-04499C5D-E078-4C67-8EB7-AEB30B9CA0B1

Q49884530-0DBE21C1-5B0B-429F-B805-620F461EB6D3

Q49884530-1409834B-0868-43F8-901D-C8E5550E0EF1

Q49884530-2569102D-745B-4D4F-88F6-C9A11C8B67D2

Q49884530-25DF93D5-CDAD-4A3F-BABA-2218FB212D00

Q49884530-36A98D30-7078-4ED5-BA6C-E77061AD7ABC

Q49884530-3B6CECE7-0A9B-4D21-A2E0-DBABEB40362B

Q49884530-4C5E2348-C37E-4F88-9520-25BA8774D781

Q49884530-4EBF1A43-1C5D-4A78-ADAD-A14BC3DD9F32

Q49884530-642BE7C5-2AB6-4A3B-B13D-38598D47AA7F

P304

Q49884530-5B8EFD36-176A-43CC-A480-23ADF35D956D

P31

Q49884530-8EE65075-449F-492C-8AC7-E90CCF12D15F

Q49884530-bf22b0d4-44f8-43ab-bc54-80cb67dacc37

P356

Q49884530-03236E06-A19A-4B51-AC73-2B2FCD5AB394

P478

Q49884530-ADF694A1-61C3-409C-911E-4EA45308B6AD

P577

Q49884530-65A81A74-708F-42B3-B2E0-2FEBB0AEB678

P698

Q49884530-5ED7CBA6-5616-46CD-9D57-2CC91B0DD9F5

P921

Q49884530-CEAD13A5-437F-43FB-B871-49C9A8873E10

P932

Q49884530-EF36AB42-59D5-41D3-9D9D-87E96B24D4CB

P356

ECANCER.2018.ED76

P1433

Ecancermedicalscience

P1476

Does the oncology community have a rejection bias when it comes to repurposed drugs?

@en

P2093

Bishal Gyawali

http://www.w3.org/2001/XMLSchema#string

Gauthier Bouche

http://www.w3.org/2001/XMLSchema#string

Pan Pantziarka

http://www.w3.org/2001/XMLSchema#string

Sergio Crispino

http://www.w3.org/2001/XMLSchema#string

P2860

Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

Same Data; Different Interpretations

Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation.

The Repurposing Drugs in Oncology (ReDO) Project.

Aspirin and cancer risk: a quantitative review to 2011.

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.

ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours

P304

ed76

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3332/ECANCER.2018.ED76

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29456622

http://www.w3.org/2001/XMLSchema#string

P921

P932

5813914

http://www.w3.org/2001/XMLSchema#string